Modification of feeding behavior

• US 7,459,432 B2
• Filed: 09/24/2002
• Issued: 12/02/2008
• Est. Priority Date: 09/24/2001
• Status: Expired due to Fees

• Current Assignee: Imperial Innovations Limited (Imperial College London), Oregon Health & Science University
• Original Assignee: Imperial College Innovations Ltd. (Imperial College London), Oregon Health & Science University
• Inventors: Small, Caroline Jane, Butler, Andrew, Bloom, Stephen Robert, Cowley, Michael, Cone, Roger, Low, Malcolm, Batterham, Rachel Louise, Ghatel, Mohammad Ali
• Primary Examiner(s): Weber; Jon P
• Assistant Examiner(s): Kosson; Rosanne
• Application Number:
  US10/490,776
• Publication Number:
  US 20050176630A1
• Time in Patent Office: 2,261 Days
• Field of Search: 514/12, 530/303, 530/324
• US Class Current: 514/1.1
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the calorie intake of the subject.

Claims

1. A method for decreasing calorie intake, food intake or appetite, in a human subject in need thereof, comprising peripherally administering prior to a meal to said subject PYY_3-36 (SEQ ID NO:

334) in a dose of from 5 to 100 nmoles per 70 to 75 kg body weight of said subject.

4. The method of claim 1, comprising peripherally administering PYY_3-36 (SEQ ID NO:

334) to said subject at least about 30 minutes prior to a meal.

5. The method of claim 1, further comprising administering an additional appetite suppressant to said subject.

6. The method of claim 1, wherein said PYY_3-36 (SEQ ID NO:

334) is administered to said subject in an amount effective to decrease calorie intake, food intake or appetite for a period of up to about 12 hours.

7. The method of claim 1, wherein the subject is overweight.

9. The method of claim 1 or 8 comprising administering PYY_3-36 (SEQ ID NO:

334) in a dose of from 5 to 90 nmoles per 70-75 kg body weight of said subject to said subject.

10. The method of claim 1 or 8 comprising administering PYY_3-36 (SEQ ID NO:

334) in a dose of from 5 to 80 nmoles per 70-75 kg body weight of said subject to said subject.

11. The method of claim 1, comprising administering said PYY_3-36 (SEQ ID NO:

334) to said subject in a sustained or depot preparation.

12. The method of claim 1 comprising administering a dose of PYY_3-36 (SEQ ID NO:

334) of from 5 to 50 nmol per 70-75 kg body weight of said subject to the subject.

13. The method of claim 5, wherein the additional appetite suppressant is selected from the group consisting of amfepramone (diethylpropion), phentermine, mazindol, phenylpropanolamine, fenfluramine, dexfenfluramine, and fluoxetine.

14. The method of claim 1 or 8 comprising administering said PYY_3-36 (SEQ ID NO:

334) modified by amidation, glycosylation, acylation, sulfation, phosphorylation, cyclisation, lipidisation or pegylation.

16. The method of claim 1 or 8 wherein the PYY_3-36 (SEQ ID NO:

334) is in the form of a controlled release preparation.

2. A method for decreasing calorie intake, food intake or appetite, in a human subject in need thereof, comprising peripherally administering prior to a meal to said subject PYY_3-36 (SEQ ID NO:

334) in a dosage of from about 45 to about 135 pmol per kilogram body weight of said subject.

3. The method of claim 2, comprising administering PYY_3-36 (SEQ ID NO:

334) in a dosage of about 72 pmol per kilogram body weight of said subject.

8. A method for treating obesity in a human subject in need of treatment comprising peripherally administering prior to a meal to said subject PYY_3-36 (SEQ ID NO:

334) in a dose of from 5 to 100 nmoles per 70-75 kg body weight of said subject.

15. A method for decreasing calorie intake, food intake or appetite, in a human subject in need thereof, comprising administering prior to a meal to said subject PYY_3-36 (SEQ ID NO:

334) in a dose of from 5 to 100 nmoles per 70 to 75 kg body weight of said subject by a rectal, intravenous, intramuscular, intranasal, intraperitoneal, intravaginal, transmucosal, sublingual or buccal route, or by pulmonary inhalation.

18. The method of claim 15 or 17 comprising administering said PYY_3-36 (SEQ ID NO:

334) modified by amidation, glycosylation, acylation, sulfation, phosphorylation, cyclisation, lipidisation or pegylation.

17. A method for treating obesity in a human subject in need thereof, comprising administering prior to a meal to said subject PYY_3-36 (SEQ ID NO:

334) in a dose of from 5 to 100 nmoles per 70 to 75 kg body weight of said subject by a rectal, intravenous, intramuscular, intranasal, intraperitoneal, intravaginal, transmucosal, sublingual or buccal route, or by pulmonary inhalation.